Возраст домена | 27 лет |
Дата окончания | Истек срок регистрации |
PR | 6 |
ИКС | 10 |
Страниц в Google | 429 |
Страниц в Яндексе | 205 |
Dmoz | Да |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 3119818 |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
MPM Capital - Powering Breakthroughs in Life Sciences
n/a
Powering Breakthroughs in Life Sciences
UTF-8
234.76 КБ
2 500
40 956 симв.
35 006 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
linkedin.com | 24 | 9 |
0 | 25 | 10 | |
bloomberg.com | 24 | 8 |
0 | 563 | 219 | |
wikipedia.org | 19 | 9 |
0 | 5 | 6 | |
facebook.com | 15 | 9 |
0 | 3 | 3 | |
bizjournals.com | 15 | 7 |
0 | 2914 | 594 | |
fiercebiotech.com | 14 | 6 |
0 | 87045 | 19580 | |
prnewswire.com | 12 | 8 |
0 | 4165 | 1298 | |
crunchbase.com | 12 | 6 |
0 | 1584 | 494 | |
google.com | 10 | 9 |
0 | 1 | 1 | |
biospace.com | 9 | 7 |
0 | 70695 | 19400 | |
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 15 Ноября 2016 ) | |
Количество ссылок на сайт | 166 |
Количество доменов, которые ссылаются на сайт | 115 |
Количество найденных анкоров | 24 |
Исходящие (внешние) ссылки домена | 643 |
Количество доменов, на которые ссылается сайт | 117 |
Количество исходящих анкоров | 77 |
Внешние ссылки главной страницы ( 153 ) | |
services.sungarddx.com/Login/ | Investor Login |
maps.google.com/maps?q=450 Kendall Street,Cambridge,MA,02142 | Get directions |
maps.google.com/maps?q=2000 Sierra Point Parkway, Suite 701,... | Get directions |
businesswire.com/news/home/20191217005165/en/Triplet-Therape... | Triplet Therapeutics Launches with $59 Million in Financing to Further Its Development of Transformative Treatments for Triplet ... |
ir.harpoontx.com/news-releases/news-release-details/harpoon-... | Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®,... |
prnewswire.com/news-releases/werewolf-therapeutics-launches-... | Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines |
prnewswire.com/news-releases/a-leading-global-medicines-comp... | Novartis and MPM Capital Invest in SiO2 Medical Products Developing a Potentially Disruptive Novel Packaging Technology |
novartis.com/news/media-releases/new-novartis-medicine-adakv... | New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sic... |
codabiotherapeutics.com/news-articles/coda-biotherapeutics-a... | CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34M |
ir.rhythmtx.com/news-releases/news-release-details/rhythm-ph... | Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering |
trinetx.com/trinetx-named-technology-partner-for-fda-sentine... | TriNetX Named Technology Partner for FDA Sentinel System |
businesswire.com/news/home/20190925005262/en/Blade-Therapeut... | Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo |
businesswire.com/news/home/20190924005339/en/Amphivena-Close... | Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop it... |
fiercebiotech.com/special-report/frontier-medicines | MPM Capital Portfolio Company Frontier Medicines Honored with a Fierce 15 Award |
reparerx.com/repare-therapeutics-announces-us82-5-million-se... | Repare Therapeutics Announces US$82.5 Million Series B Financing |
semma-tx.com/media1/vertex-to-acquire-semma-therapeutics-wit... | Semma Therapeutics to be Acquired by Vertex for $950M |
iconictherapeutics.com/wp-content/uploads/2019/08/press-rele... | Iconic Therapeutics Signs Ophthalmology Option Agreement with Novartis |
oncorus.com/news-items/2019/8/20/oncorus-announces-795-milli... | Oncorus Announces $79.5 Million Series B Financing to Support the Advancement of Oncolytic Virus Therapies to Transform Outcomes... |
ir.chiasmapharma.com/news-releases/news-release-details/chia... | Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common Stock |
elevate.bio/press-release-blog/massachusetts-general-hospita... | MGH and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene ... |
frontiermeds.com/press_release/frontier-medicines-launches-w... | Frontier Medicines Launches with $67M Series A Financing |
allovir.com/news-blog/elevatebio-announces-that-allovir-join... | Portfolio Company ElevateBio Announces that Allovir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies |
iconictherapeutics.com/wp-content/uploads/2019/05/EXEL-Iconi... | Iconic Therapeutics And Exelixis Enter into Exclusive Option and License Agreement for Novel Antibody-drug Conjugate Program |
elevate.bio/press-release-blog/elevatebio-launches-to-create... | ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies |
aratana.investorroom.com/2019-04-26-Aratana-Therapeutics-to-... | Aratana Therapeutics to be Acquired by Elanco Animal Health |
businesswire.com/news/home/20190403005159/en/Dyne-Therapeuti... | Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases |
trinetx.com/seriesD/ | TriNetX Secures $40 Million in Series D Funding |
news.embl.de/alumni/2019-alumni-awards/?_ga=2.84962073.14655... | MPM’s Patrick A. Baeuerle Awarded the 2019 Lennart Philipson Award for Contributions to Cancer Immunotherapy |
biocentury.com/biocentury/finance/2019-02-22/how-mpm-deployi... | BioCentury: MPM Keeps Building |
wsj.com/articles/biotech-investor-mpm-capital-refuels-with-4... | The Wall Street Journal: Biotech Investor MPM Capital Refuels With $400 Million Venture Fund |
scrip.pharmaintelligence.informa.com/SC124706/MPM-Raises-$40... | Scrip Pharma intelligence: MPM Raises $400M To Build Early-Stage Biotechs |
endpts.com/mpm-adds-408m-for-its-next-big-wave-of-biotech-st... | Endpoints News: MPM Adds $408M for its Next Big Wave of Biotech Startups — and Oncology Still Dominates the Menu |
hbr.org/2018/12/impact-investing-could-accelerate-the-fight-... | Harvard Business Review: Impact Investing Could Accelerate the Fight Against |
globenewswire.com/news-release/2019/01/03/1680172/0/en/Tizon... | Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-i... |
prnewswire.com/news-releases/abbvie-and-tizona-therapeutics-... | Tizona Therapeutics and AbbVie Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD3... |
entradatx.com/news/entrada-therapeutics-raises-usd59-million... | Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform |
static1.squarespace.com/static/5b88a5aa4611a0e9a123a225/t/5c... | TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 Event |
harpoontx.com/news/111118/ | Harpoon Therapeutics Announces Closing of $70M Series C Financing |
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsArti... | Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules |
codabiotherapeutics.com/news/ | MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy Platform |
businesswire.com/news/home/20180906005256/en/Twentyeight-Sev... | Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding |
harpoontx.com/news/080618/ | Harpoon Therapeutics Treats First Patient With HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Canc... |
oncorus.com/news-items/2018/8/1/oncorus-inc-names-industry-v... | Oncorus®, Inc., Names Industry Veteran Ted Ashburn as new President and CEO |
mavericktx.com/press/maverick-therapeutics-advances-technolo... | Maverick Therapeutics Advances Technology; Adds Key Management |
iteostherapeutics.com/node/149 | MPM Executive Partner, David Hallal, Appointed Chairman of iTeos Therapeutics |
businesswire.com/news/home/20180626005732/en/Immunotherapy-P... | Patrick Baeuerle, MPM Executive Partner and Immunotherapy Pioneer, to Present Compelling Data from Harpoon Therapeutics’ Biother... |
iteostherapeutics.com/node/148 | MPM Leads $75 Million Series B Financing of iTeos Therapeutics |
medpagetoday.com/publichealthpolicy/generalprofessionalissue... | MPM Cancer Research Partnership with AACR Featured in Medpage Today |
semma-tx.com/media1/semma-therapeutics-appoints-bastiano-san... | MPM Portfolio Company Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as CEO and President |
blogs.thomsonreuters.com/sustainability/2018/05/04/executive... | Chris Bardon Comments to Reuters on the OIF and its Philanthropic Impact |
youtube.com/watch?v=gsH81W0GFNI&feature=youtu.beLinke | Watch Now: Chris Bardon is a Featured Panelist at Paying for Cures – Global Conference 2018 | Milken Institute |
bioworld.com/report/BWIS04232018AACR_UBS.pdf | MPM’s Approach to Investing is Positively Impacting Cancer Research and Care |
prnewswire.com/news-releases/tetherex-pharmaceuticals-inc-co... | MPM Capital Portfolio Company Tetherex Pharmaceuticals Completes $50M Series B Financing |
vimeo.com/centercityvideo/review/266769715/768541d89f | Watch Now: Press Event Announcing MPM and AACR Partnership in Cancer Research |
barrons.com/articles/ubs-oncology-impact-fund-announces-2-5m... | MPM and AACR Partnership Featured in Barron’s Article “UBS Oncology Impact Fund Announces $2.5M in Gifts” |
webcast.aacr.org/console/player/39425?mediaType=slideVideo& | Watch Now: Chris Bardon Announces MPM and AACR Partnership in Cancer Research at AACR 2018 Opening Ceremony |
bioworld.com/report/BWT040918Incyte.pdf | MPM’s Chris Bardon Comments on Lessons Learned from Recent IO Trial Results |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/5a... | MPM Portfolio Company TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing |
businesswire.com/news/home/20180220005842/en | Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics |
newsroom.astellas.us/2018-01-23-Astellas-Completes-Acquisiti... | Astellas Completes Acquisition of Mitobridge, Inc. |
bioworld.com/report/BWT011118Women.pdf | BioWorld’s Key Highlights from the Women in Bio and Bloomberg Intelligence Panel with Chris Bardon at JPM18 |
syndax.com/wp-content/uploads/2018/01/PR_SNDX-Roche-BC-Agree... | Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunothera... |
cnbc.com/video/2018/01/09/whats-working-investing-in-health-... | WATCH NOW: Chris Bardon Discusses the Cycle of Innovation and Value of Transformative Therapies on CNBC |
prnewswire.co.uk/news-releases/wuxi-nextcode-artificial-inte... | Rhythm Pharmaceuticals Enters into Partnership with WuXi NextCODE the Emerging Global Standard Platform for Genomic Data |
bioworld.com/report/BWT010818JPM.pdf | Chris Bardon Shares her Thoughts on Market Trends and Innovative Therapies with BioWorld |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/5a... | TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference |
forbes.com/sites/matthewherper/2017/12/09/scientists-could-c... | Chris Bardon Comments on Positive Gene Therapy Data in Forbes article, “Excitement Builds Around Gene Therapy Cures For Hemophil... |
astellas.com/en/news/9926 | MPM portfolio company, Mitobridge, Inc. to be acquired by Astellas Pharmaceuticals in a deal worth up to $450 million |
semma-tx.com/media1/semma-therapeutics-raises-114-million-se... | Semma Therapeutics Raises $114m for Novel Diabetes Treatment |
ir.syndax.com/releasedetail.cfm?ReleaseID=1044162 | Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL Inhibitors |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/59... | TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer |
blademed.com/news/oct-18-2017/ | Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B Fi... |
prnewswire.com/news-releases/abbvie-and-harpoon-therapeutics... | AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration |
bloomberg.com/news/features/2017-10-17/one-scientist-s-marat... | Mitobridge featured in Bloomberg article, “One Scientist’s Marathon Quest for the Exercise Pill” |
ir.rhythmtx.com/phoenix.zhtml?c=253719&p=irol-newsArticle&ID... | Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering |
oncorus.com/news-items/2017/10/3/oncorus-inc-names-christoph... | Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer |
cullinanoncology.com/2017/10/03/cullinan-oncology-secures-15... | The UBS Oncology Impact Fund Co-leads $150 Million Series A Financing of Cullinan Oncology |
reparerx.com/new-post/ | Repare Therapeutics Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2017 |
wxpress.wuxiapptec.com/inside-perspectives-gene-editing-inte... | Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell Finer |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/59... | TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers |
oncorus.com/news-items/2017/9/14/scientists-see-progress-for... | Oncorus’ Viral Cancer Vaccine Highlighted in WSJ: “Scientists See Progress for Cancer Vaccines” |
wxpress.wuxiapptec.com/inside-perspectives-mpms-christiana-b... | Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon |
tcr2.com/ | TCR2 |
bioworld.com/content/gene-therapy-cloaked-cell-therapy-arriv... | MPM’s Chris Bardon Applauds Novartis’ Value-Based Pricing Move for its CAR-T Cell Therapy Kymriah |
businesswire.com/news/home/20170810005191/en/Maverick-Therap... | Maverick Therapeutics Appoints James S. Scibetta as CEO |
bioworld.com/content/lilly-glaxosmithkline-moves-shake-partn... | MPM’s Chris Bardon Talks to BioWorld About Recent Pharma R&D Restructuring |
ir.radiuspharm.com/releasedetail.cfm?ReleaseID=1033291 | Radius Health Appoints Jesper Høiland as President and Chief Executive Officer |
wsj.com/articles/scientists-take-new-approach-to-fighting-ty... | Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack” |
businesswire.com/news/home/20170622005202/en | MPM and Versant Venture Co-Lead Series A Financing of Repare Therapeutics |
globenewswire.com/news-release/2017/06/22/1027742/0/en/Prote... | Proteon Therapeutics Announces $22.0 Million Private Placement |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/59... | TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Cong... |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=102892... | Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the ... |
endpts.com/amgen-vet-patrick-baeuerle-inspires-a-45m-round-f... | Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform |
businesswire.com/news/home/20170525005333/en/Harpoon-Therape... | Harpoon Therapeutics Announces Completion of $45M Series B Financing |
businesswire.com/news/home/20170523005780/en/Bioverativ-Acqu... | MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc |
endpts.com/syndax-shares-soar-as-lead-drug-clears-a-mid-stag... | Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle |
ir.conatuspharma.com/releasedetail.cfm?ReleaseID=1024672 | Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initi... |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=102355... | FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide) |
labiotech.eu/interview-patrick-baeuerle-biotech/ | Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle |
mmm-online.com/top-40-transformers/mpm-capital-oncology-impa... | MPM Managing Director Chris Bardon Named a Top-40 Transformer |
bizjournals.com/boston/news/2017/04/04/here-are-the-2017-new... | MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics |
ir.syndax.com/releasedetail.cfm?ReleaseID=1020011 | Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors |
rhythmtx.com/news-resources/press-releases/rhythm-announces-... | Rhythm Announces Completion of $41 Million Mezzanine Financing |
takeda.com/news/2017/20170111_7659.html | MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies |
businesswire.com/news/home/20170104006164/en/Accomplished-Bi... | Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director |
bio-techne.com/press-releases/press/20161214 | MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne |
novartis.com/news/media-releases/novartis-announces-exclusiv... | Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc. |
oncorus.com/news-items/2016/12/15/oncorus-inc-announces-addi... | Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC |
businesswire.com/news/home/20161213006275/en/Harpoon-Therape... | Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO |
static1.squarespace.com/static/581760e96b8f5b0e59bf9daa/t/58... | TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies |
bloomberg.com/news/articles/2016-12-02/a-few-billionaires-ar... | Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy |
amda-1rbic2.client.shareholder.com/releasedetail.cfm?Release... | Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update |
novartis.com/news/media-releases/novartis-acquires-selexys-p... | Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in S... |
businesswire.com/news/home/20161108005175/en/Harpoon-Therape... | Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer |
semma-tx.com/media1/semma-therapeutics-announces-mark-fishma... | Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman |
amda-1rbic2.client.shareholder.com/releasedetail.cfm?Release... | MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the Nationa... |
motustx.com/news-resources/press-releases/allergan-acquire-g... | Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan |
fiercepharma.com/special-report/kristen-williams-pacira-phar... | Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016” |
iomx.de/wp-content/uploads/2016/09/20160922_iOmx_Series-A-PR... | iOmx Therapeutics Raises EUR 40 Million in Series A round |
fiercebiotech.com/special-report/fiercebiotech-s-2016-fierce... | Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=989784 | Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment |
nytimes.com/2016/08/17/health/osteoporosis-a-disease-with-fe... | NY Times |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=984545 | Press Release |
aratana.investorroom.com/2016-08-15-Aratana-Therapeutics-Gra... | Aratana Secures Third FDA Approval |
statnews.com/2016/08/09/george-daley-harvard-medical-school-... | Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean |
iconictherapeutics.com/wp-content/uploads/2016/08/SRS-C-fina... | Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment |
astellas.com/en/corporate/news/detail/astellas-launches-digi... | Astellas and MPM Capital Launch DigiTx Partners |
rhythmtx.com/news-resources/press-releases/rhythm-announces-... | Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obes... |
biospace.com/News/former-bluebird-bio-cso-takes-the-reins-at... | Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A |
statnews.com/2016/06/16/stem-cell-diabetes-treatment/ | MPM Portfolio Company Semma Therapeutics Featured in Boston Globe |
vimeo.com/169416963/8534f107d1 | Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets |
aratana.investorroom.com/2016-03-21-Aratana-Therapeutics-Gra... | Aratana Therapeutics Granted First FDA Approval |
ir.chiasmapharma.com/phoenix.zhtml?c=254057&p=irol-newsArtic... | Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly |
businesswire.com/news/home/20160308005372/en/Tizona-Therapeu... | Tizona Therapeutics, Inc., Completes $43 Million Series B Financing |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=962756 | Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Po... |
syndax.com/wp-content/uploads/2016/03/SNDX_News_2016_3_2_Gen... | Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market |
iconictherapeutics.com/wp-content/uploads/2015/04/Iconic-The... | Iconic Therapeutics Closes Series C Financing |
fiercemedicaldevices.com/special-reports/semma-therapeutics-... | Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15 |
news.sys-con.com/node/3428635 | Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab |
prnewswire.com/news-releases/rhythm-subsidiary-raises-40-mil... | Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing |
ir.chiasmapharma.com/phoenix.zhtml?c=254057&p=irol-newsArtic... | Chiasma, Inc. Prices Initial Public Offering of Common Stock |
pehub.com/2015/07/taking-clinical-trials-out-of-the-dark-age... | Taking Clinical Trials Out of the Dark Ages (Clinical Ink) |
chiasmapharma.com/news/chiasma-submits-new-drug-application-... | Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly |
bostonglobe.com/business/2015/03/23/biotech-startup-semma-th... | Biotech Startup to Fight Diabetes on the Cellular Front |
chiasmapharma.com/news/chiasma-announces-mark-leuchtenberger... | Chiasma Announces Mark Leuchtenberger as Chief Executive Officer |
investors.radiuspharm.com/releasedetail.cfm?ReleaseID=900493 | Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan |
phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArtic... | Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma |
prnewswire.com/news-releases/chiasma-appoints-david-stack-as... | Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors |
xconomy.com/boston/2015/02/17/syndax-ceo-says-an-immuno-onco... | Syndax Says Immuno-oncology Discovery Happened Instead of an IPO |
news.fidelity.com/news/news.jhtml?cat=Opinion&articleid=2015... | Radius, Celladon and Nevro Among Top IPOs in 2014 |
news.investors.com/technology/122414-732039-radius-auspex-ki... | Radius: The Top Performing IPO of 2014 |
nytimes.com/2014/08/02/business/biotechnology-for-treating-d... | Aratana Featured: Start-Ups Work on Biotech Drugs for Pets |
mpmcapital.altareturn.com | Investor Login |
Внутренние ссылки главной страницы ( 52 ) | |
#top | back to top |
/contact?print | |
/terms-of-use | Terms Of Use & Disclosures |
mpmcapital.com/press/the-aacr-mpm-oncology-charitable-founda... | The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research |
mpmcapital.com/press/mpms-todd-foley-comments-on-pharma-mark... | MPM’s Todd Foley Comments on Pharma Market in WSJ Pro VC “Pharma Mergers, Strong IPO Market Mute Startup Acquisitions” |
mpmcapital.com/press/mpm-capital-executive-partner-patrick-b... | MPM Capital Executive Partner Patrick Baeuerle Wins 2019 Xconomy “X of the Year” Award |
mpmcapital.com/press/mpms-todd-foley-discusses-acquisition-o... | MPM’s Todd Foley Discusses Acquisition of Semma Therapeutics in WSJ Pro VC “Vertex Makes Another Aggressive Purchase With Semma” |
mpmcapital.com/aacrmpmgrants/ | AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program Now Inviting Applications |
mpmcapital.com/press/2557-2/ | MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation |
mpmcapital.com/press/mpm-capital-expands-its-team-of-executi... | MPM Capital Expands its Team of Executive Partners and Entrepreneurs with the Appointments of Biotech Leaders Detlev Biniszkiewi... |
mpmcapital.com/press/chris-bardon-talks-to-wsj-pro-vc-about-... | Chris Bardon Talks to WSJ Pro VC about Late-Stage Combination Therapy Trials |
mpmcapital.com/press/mpms-partnership-with-aacr-highlighted-... | MPM’s Partnership with AACR Highlighted in WSJ Pro VC “Gormley’s Take: Health-Care Investors Doing Good After Doing Well” |
mpmcapital.com/press/the-aacr-and-the-ubs-oncology-impact-fu... | MPM and AACR Announce Partnership in Cancer Research |
mpmcapital.com/press/gormleys-take-writing-war-cancers-next-... | Gormley’s Take: Writing War on Cancer’s Next Chapter –– Biotech startups seek to widen benefits of revolutionary cell-therapy tr... |
mpmcapital.com/team/christiana-bardon-m-d/ | Chris Bardon |
mpmcapital.com/press/visionary-scientist-stephen-j-elledge-j... | Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory Board |
mpmcapital.com/press/accomplished-oncologist-scientist-willi... | Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory Board |
mpmcapital.com/press/chris-varma-co-founder-former-president... | Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence |
mpmcapital.com/press/true-north-therapeutics-receives-fda-or... | True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Includ... |
mpmcapital.com/press/tizona-therapeutics-inc-appoints-george... | Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors |
mpmcapital.com/press/1962-2/ | Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More |
mpmcapital.com/wp-content/uploads/2016/07/July-19-San-Franci... | MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times |
mpmcapital.com/press/trinetx-enters-collaboration-celgene/ | TriNetX Enters into Collaboration with Celgene |
mpmcapital.com/press/aratana-therapeutics-granted-fda-approv... | Aratana Therapeutics Granted FDA Approval of ENTYCE® |
mpmcapital.com/press/mpm-launches-471-million-social-impact-... | MPM Launches $471 Million Social Impact Oncology Fund |
mpmcapital.com/press/ubs-cancer-fund-shows-power-impact-inve... | UBS Cancer Fund Shows Power of Impact Investing |
mpmcapital.com/press/ubs-mpm-seek-big-impact-cancer-drugs-47... | UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund |
mpmcapital.com/press/ubs-raises-record-471-million-oncology-... | UBS Raises Record $471 Million for Oncology Impact Fund |
mpmcapital.com/press/syndax-raises-80-million-in-series-c-fi... | Syndax Raises $80 Million in Series C Financing |
mpmcapital.com/press/epizyme-appoints-robert-bazemore-presid... | Epizyme Appoints Robert Bazemore President and Chief Executive Officer |
mpmcapital.com/press/briggs-w-morrison-m-d-ceo-of-syndax-app... | Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital |
mpmcapital.com/press/k-peter-hirth-phd-joins-iconic-therapeu... | K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor |
mpmcapital.com/press/mpm-capital-appoints-pablo-j-cagnoni-m-... | MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunoth... |
mpmcapital.com/press/mpm-closes-400-million-fund/ | MPM closes $400 million fund |
mpmcapital.com/press/23andme-launches-the-lupus-research-stu... | 23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. |
mpmcapital.com/press/astellas-pharma-and-potenza-therapeutic... | Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics |
mpmcapital.com/press/mpm-capital-announces-novartis-internat... | Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015 |
mpmcapital.com/press/semma-therapeutics-announces-44-million... | Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Sig... |
mpmcapital.com/press/ebb-flow-chiasmas-private-decision/ | Ebb & Flow: Chiasma’s Private Decision |
mpmcapital.com/press/23andme-create-therapeutics-group-appoi... | 23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead |
mpmcapital.com/press/mpm-capital-announces-immuno-oncology-p... | MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director |
mpmcapital.com/press/chiasma-announces-completion-70-million... | Chiasma Announces Completion of $70 Million Series E Financing |
mpmcapital.com/press/chiasma-inc-releases-newly-published-ph... | Chiasma Inc. Releases Newly Published Phase 3 Study Results |
mpmcapital.com/press/radius-announces-positive-phase-3-top-l... | Radius Announces Positive Phase 3 Top-Line Results |
mpmcapital.com/press/venture-capital-biotech-really/ | For Venture Capital, Biotech is Where It’s Really At |
mpmcapital.com/press/true-north-snags-22m-sets-course-clinic... | True North snags $22M and sets course for the clinic with a rare disease drug |
mpmcapital.com/press/iperian-acquired-by-bristol-myers-squib... | iPierian acquired by Bristol-Myers Squibb |
mpmcapital.com/press/iconic-therapeutics-raises-20-million-t... | Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program |
/wp-content/uploads/pdf/Celladon_MYDICAR_Breakthrough_Design... | Celladon Receives Breakthrough Therapy Designation from FDA |
mpmcapital.com/press/costim-pharmaceuticals-inc-acquired-by-... | CoStim Pharmaceuticals, Inc. Acquired by Novartis |
mpmcapital.com/press/mpm-capital-and-kleiner-perkins-caufiel... | MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs |
mpmcapital.com/press/epizyme-and-celgene-advance-epz-5676-do... | Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving... |
Domain Name: MPMCAPITAL.COM
Registry Domain ID: 2320079_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2017-01-03T11:05:56Z
Creation Date: 1997-02-28T05:00:00Z
Registry Expiry Date: 2020-03-01T05:00:00Z
Registrar: Network Solutions, LLC.
Registrar IANA ID: 2
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS10.DNSMADEEASY.COM
Name Server: NS11.DNSMADEEASY.COM
Name Server: NS12.DNSMADEEASY.COM
Name Server: NS13.DNSMADEEASY.COM
Name Server: NS14.DNSMADEEASY.COM
Name Server: NS15.DNSMADEEASY.COM
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-18T13:47:58Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
США - Атланта - 74.63.178.17
ViaWest Internet Services
ViaWest
HTTP/1.1 200 OK
Server: nginx
Date: Wed, 18 Dec 2019 23:33:12 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 240393
Connection: keep-alive
Keep-Alive: timeout=20
Vary: Accept-Encoding
Link: ; rel="https://api.w.org/"
X-Cacheable: SHORT
Vary: Accept-Encoding,Cookie
Cache-Control: max-age=600, must-revalidate
X-Cache: HIT: 2
X-Pass-Why:
X-Cache-Group: normal
Accept-Ranges: bytes
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"